The Athens Stock Exchange welcomed today the management, executives, and partners of Lavipharm to mark the one-year anniversary of the company’s share capital increase. Telemachos Lavidas, Executive Board Member of Lavipharm, rang the opening bell to commence the trading session.

In his address, Yianos Kontopoulos, CEO of the Athens Exchange Group, referred to Lavipharm’s success as a challenging endeavor that was ultimately won: “The success of this initiative reflected investors’ confidence in Lavipharm and laid new foundations for its growth and further consolidation, both in Greece and internationally. One year after its capital increase, Lavipharm’s market capitalization exceeds €110 million, and its share price has risen by approximately 100%. Just as we warmly welcome every new company to the Stock Exchange, we equally celebrate every successful turnaround and growth effort of a listed company, such as that of Lavipharm. The dedicated and substantial efforts of any business to execute its investment plan deserve and will always have our support.”

For his part, Mr. Telemachos Lavidas, Executive Board Member of Lavipharm, stated: “One year ago, we shared our challenges with the investment community with transparency and honesty, along with our five-year plan, which was designed around a demanding capital increase. A year later, we have exceeded the targets set in that plan. Lavipharm’s stock is now listed on the Main Market, included in the ATHEX ESG index, and part of the FTSE Russell Microcap index. Our success is the result of a clear strategy, consistent execution, outstanding human capital, hard work, and unwavering determination to reach the top.”